在早期阿尔茨海默氏症的多纳纳马布的资格:一个现实世界的研究研究
Daniele Urso1, Alessandro Introna2, Valentina Gnoni1
1Center for Neurodegenerative Diseases and the Aging Brain, Department of Clinical Research in Neurology, University of Bari 'Aldo Moro', Tricase, Italy.
Journal of Alzheimer's disease : JAD
|May 2, 2025
概括
很少有早期阿尔茨海默病患者符合donanemab资格. 这种针对免疫治疗的粉样质斑块显示了临床试验和真实世界患者访问之间的显著差距,这对广泛的临床使用构成了挑战.
科学领域:
- 神经学 神经学
- 免疫治疗是一种免疫疗法.
- 临床药理学 临床药理学
背景情况:
- 阿尔茨海默病 (AD) 是一种进展性神经退行性疾病.
- 粉样斑块是AD的关键病理标志.
- 多纳尼马布是一种针对粉样斑块的试验性单克隆抗体.
研究的目的:
- 评估早期阿兹海默症患者在现实世界中是否有资格接受多纳尼马布治疗.
- 在常规临床环境中识别donanemab资格障碍.
主要方法:
- 在第三级中心对408名轻度认知障碍或轻度AD患者的回顾性分析.
- 根据donanemab临床试验资格标准进行评估.
- 评估粉样蛋白生物标志物状态,医疗状况和MRI发现.
主要成果:
- 41%的患者是粉样蛋白阳性.
- 只有10.05%的患者符合donanemab的所有资格标准.
- 排除原因包括粉样蛋白生物标志物值,并发病症和MRI异常.
结论:
- 在临床试验群体和现实患者之间,对于donanemab的资格存在重大差异.
- 在临床实践中扩大对donanemab的使用范围需要解决符合条件和患者选择的问题.
- 在日常护理中实施抗粉样蛋白免疫疗法时,平衡治疗疗效与安全至关重要.
更多相关视频
09:33Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
7.9K
09:47Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
Published on: December 15, 2023
899
相关概念视频
Alzheimer's Disease: Treatment
128
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
128
Alzheimer's Disease: Overview
315
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
315
Dementia
64
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
64
